Rare Disease

Latest News

red blood cells and white blood cells
Samsung Bioepis' Eculizumab Biosimilar Approved in Europe

May 31st 2023

The European Commission has granted marketing authorization to Samsung Bioepis' biosimilar referencing Soliris (eculizumab). The product, dubbed Epysqli, is the first hematology biosimilar from Samsung Bioepis to be approved in the European Union.

Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points
Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points

August 24th 2022

Opinion: Biosimilars Can Aid in Post–COVID-19 Health Care Financial Recovery
Opinion: Biosimilars Can Aid in Post–COVID-19 Health Care Financial Recovery

June 19th 2021

Medicines for Europe Panel Targets Waste in Health Care, Need for Education
Medicines for Europe Panel Targets Inefficiencies, Need for Education

May 28th 2021

Samsung Bioepis Wins Biosimilar Package Design Awards
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging

April 24th 2021

More News

© 2023 MJH Life Sciences

All rights reserved.